Improving production capacity in "GALEN-N" Ltd."

This project proposal is aimed at purchase and commissioning of a semi-automated line for the production of active pharmaceutical substances (APhS), including: Spray dryer - 1 pc.; Rotor sieve - 1 pc.; Channel gas chromatograph - 1 pc.; Dryer with forced convection - 1 pc. and Evaporator - 1 pc. The integration in production process of this equipment will overcome the limitations of the capacity of production of active pharmaceutical substances, leading to limitations in taking new orders from existing and new clients of the company. Limitations in manufacturing are caused by insufficient technological capacity, lack of process automation and inability to process the entire volume of waste weight serving as a raw material in the manufacture of APhS. The planned for implementdtiom project activities relate to code of economic activities 21:10 - Production of drugs, that in 2014 has been declared a 6% of the total turnover of the company. The new assets are hightechnologival and their introduction into production will ensure quality control of the products. It will increase production capacity of APhS by over 300%, will optimize production time by 50% necessary for the complete production process. This will positively affect the productivity of "Galena - H" Ltd. and will increase the production capacity of the company, and hence the amount of exported products. The new machines are high-tech, semi-automated and extremely precise, leading to productivity growth by over 24% in a period of three years after implementation of the project the average revenue generated from exports rise above 124%, increase in efficiency over 16% due to the improvement of resource efficiency in the company. The project is implemented in the "Industry for a healthy life and bio-technology" of the Innovative Strategies for Intelectual Specialization.

Comments
Leave a comment

Overview

Status Closed (completion date)
Start date 09 Feb, 2016
End date 23 Oct, 2017
Contract date 09 Feb, 2016
View in UMIS

Beneficiary

Financial information

Total cost 1,071,323.59
Grant 749,926.51
Self finance 321,397.08
Total paid 749,311.50
EU participation percent 85.0%

Location